196 related articles for article (PubMed ID: 34481528)
21. Pneumocystis jirovecii Pneumonia and Other Infections in Idiopathic Inflammatory Myositis.
Mecoli CA; Danoff SK
Curr Rheumatol Rep; 2020 Feb; 22(2):7. PubMed ID: 32020305
[TBL] [Abstract][Full Text] [Related]
22. Healthcare-associated Pneumocystis jirovecii Pneumonia (PJP) Infection in HIV-negative Adults: a Multicenter Study.
Zalmanovich A; Ben-Ami R; Rahav G; Alon D; Moses A; Olshtain-Pops K; Weinberger M; Shitrit P; Katzir M; Gottesman BS; Chowers M
Isr Med Assoc J; 2021 May; 23(5):312-317. PubMed ID: 34024049
[TBL] [Abstract][Full Text] [Related]
23. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases.
Zhang Y; Zheng Y
Rheumatol Int; 2014 Dec; 34(12):1765-71. PubMed ID: 24948376
[TBL] [Abstract][Full Text] [Related]
24. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
Mecoli CA; Saylor D; Gelber AC; Christopher-Stine L
Clin Exp Rheumatol; 2017; 35(4):671-673. PubMed ID: 28134084
[TBL] [Abstract][Full Text] [Related]
25. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.
Ryan CE; Cheng MP; Issa NC; Brown JR; Davids MS
Blood Adv; 2020 Apr; 4(7):1458-1463. PubMed ID: 32282880
[TBL] [Abstract][Full Text] [Related]
26. Rapidly progressive interstitial lung disease combined with pneumocystis jiroveci pneumonia in a patient with single anti-TIF-1γ antibody positive dermatomyositis in the context of an underlying tumor.
Zhang H; Yue J; Hou X; Lu H; Bikdeli A; Guo H; Li H; Li D
BMC Pulm Med; 2023 Jul; 23(1):248. PubMed ID: 37415133
[TBL] [Abstract][Full Text] [Related]
27. Association of Cytomegalovirus Infection With Anti-MDA5 Antibody-Positive Dermatomyositis: A Prospective Cohort Study.
Huang L; Zhu W; Ye Y; Wu X; Yan Q; Wang Z; Lin Y; Chen S
Front Med (Lausanne); 2021; 8():740154. PubMed ID: 34692731
[No Abstract] [Full Text] [Related]
28. Plasma proteomic profiling reveals KRT19 could be a potential biomarker in patients with anti-MDA5+ dermatomyositis.
Zhang P; Li M; Zhang Y; Lian C; Sun J; He Y; Hu W; Wang L; Li T; Liu S; Zhang Y
Clin Rheumatol; 2023 Aug; 42(8):2145-2154. PubMed ID: 37160775
[TBL] [Abstract][Full Text] [Related]
29. Pneumocystis jirovecii pneumonia in African miners at autopsy.
Wong ML; Back P; Candy G; Nelson G; Murray J
Int J Tuberc Lung Dis; 2006 Jul; 10(7):756-60. PubMed ID: 16848337
[TBL] [Abstract][Full Text] [Related]
30. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
[TBL] [Abstract][Full Text] [Related]
31. Risk factors associated with Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-pathogens analysis by metagenomic next-generation sequencing.
Huang L; Xu S; Huang Z; Chen Y; Xu N; Xie B
BMC Pulm Med; 2023 Feb; 23(1):72. PubMed ID: 36829171
[TBL] [Abstract][Full Text] [Related]
32. Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab.
Park JW; Curtis JR; Choi SR; Kim MJ; Ha YJ; Kang EH; Lee YJ; Lee EB
Arthritis Rheumatol; 2023 Nov; 75(11):2036-2044. PubMed ID: 37096489
[TBL] [Abstract][Full Text] [Related]
33. Late-onset Pneumocystis jirovecii pneumonia post-allogeneic stem cell transplantation after time-dependent discontinuation of prophylaxis.
Stavi V; Desai N; Michelis FV; Kim DDH; Kumar R; Lipton JH; Law AD
Eur J Haematol; 2024 Mar; 112(3):433-438. PubMed ID: 37947314
[TBL] [Abstract][Full Text] [Related]
34. The risk factor analysis and treatment experience in pneumocystis jirovecii pneumonia after kidney transplantation.
Yang P; Zhu X; Liang W; Cai R
Mycoses; 2021 May; 64(5):495-502. PubMed ID: 33368732
[TBL] [Abstract][Full Text] [Related]
35. Single-center retrospective analysis of Pneumocystis jirovecii pneumonia in patients after deceased donor renal transplantation.
Zou J; Wang T; Qiu T; Zhou J; Chen Z; Ma X; Jin Z; Xu Y; Zhang L
Transpl Immunol; 2022 Jun; 72():101593. PubMed ID: 35367619
[TBL] [Abstract][Full Text] [Related]
36. Characterization and associated risk factors of Pneumocystis jirovecii pneumonia in patients with AIRD: a retrospective study.
Zhao Z; Huang Y; Ming B; Zhong J; Dong L
Rheumatology (Oxford); 2022 Aug; 61(9):3766-3776. PubMed ID: 34962999
[TBL] [Abstract][Full Text] [Related]
37. [Pneumocystis jirovecii and quantitative PCR: Pneumonia or colonization?].
Gazaignes S; Bergeron A; Menotti J; Desseaux K; Molina JM; De Castro N
Rev Mal Respir; 2020 Apr; 37(4):299-307. PubMed ID: 32273116
[TBL] [Abstract][Full Text] [Related]
38.
Li J; Li J; Yu Y; Wang R; Zhou M; Lu L
Rheumatol Adv Pract; 2022; 6(1):rkab105. PubMed ID: 35028498
[TBL] [Abstract][Full Text] [Related]
39. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
Sidhu VK; Foisy MM; Hughes CA
Ann Pharmacother; 2015 Dec; 49(12):1343-8. PubMed ID: 26358129
[TBL] [Abstract][Full Text] [Related]
40. Lower incidence of Pneumocystis jirovecii pneumonia among Africans in the Netherlands host or environmental factors?
Schoffelen AF; van Lelyveld SF; Barth RE; Gras L; de Wolf F; Netea MG; Hoepelman AI;
AIDS; 2013 Apr; 27(7):1179-84. PubMed ID: 23276810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
